Professor of Medicine, University Ariz College of Medicine
Hematology
Dr. Frederick R. Ahmann, MD
|
|
Give Review
Dr. Frederick R. Ahmann works in the field of Hematology. He went to University of Missouri-Columbia School of Medicine. He over the years received 3 awards: "America's Top Doctors", "Top Doctors:Arizona State" and "America's Top Doctors for Cancer". Frederick Ahmann has written publications. He has 82 publications published with PubMed. The lastest paper is: 'Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.' He accepts all Medicare patients.
Publications
- Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate Cancer.
- Mixed germ cell testicular Cancer with left ventricular metastasis presenting with embolic stroke and small bowel tumor seeding.
- Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate Cancer a...
- Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate Cancer: a report from the ...
- Coccidioidomycosis of the Prostate: a determination of incidence, report of 4 cases, and treatment recommendations.
- No effect of selenium supplementation on serum glucose levels in men with prostate Cancer.
- Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate Cancer.
- Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity.
- Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities.
- Association of Obesity and Smoking With PSA and PSA Velocity in Men With Prostate Cancer.
- Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate Carcinoma.
- In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios.
- Allopurinol and bolus fluorouracil.
- A current view of prostatic Cancer.
- Phase II trial of CHIP for the treatment of advanced, hormonally refractory Carcinoma of the prostate. A Southwest Oncology Group Study.
- Treatment of Cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
- Phase II trial of amonafide for the treatment of advanced, hormonally refractory Carcinoma of the prostate. A Southwest Oncology Group study.
- Neoadjuvant therapy for advanced head and neck Cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. A phase I-II study.
- Dose-dependent effects of selenized yeast on total selenium levels in prostatic tissue of men with prostate Cancer.
- Extensive non-small cell lung Cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.
- ATP assay: ability to distinguish cytostatic from cytocidal antiCancer drug effects.
- MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate Cancer with biochemical failure.
- Selenium and inhibition of disease progression in men diagnosed with prostate Carcinoma: study design and baseline characteristics of the ''Watchful Waiting'' Study.
- Selenium and prevention of prostate Cancer in high-risk men: the Negative Biopsy Study.
- Palliation of pain associated with metastatic bone Cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
- Prostatic asymmetry as a risk factor for prostatic carcinoma: serial prostate-specific antigen monitoring and Cancer detection.
- Ketoconazole-induced Adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature.
- Prospective longitudinal evaluation of men with initial Prostate specific antigen levels of 4.0 ng./ml. or less.
- Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain.
- Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate Cancer.
- Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic Carcinoma.
- Leukoerythroblastic anemia in metastatic prostate Cancer. Clinical and prognostic significance in patients with hormone-refractory disease.
- Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic Carcinoma.
- Effect of patient age on early detection of prostate Cancer with serum prostate-specific antigen and digital rectal examination.
- Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic Carcinoma.
- Prostate-specific antigen obtained under optimal conditions determines extracapsular adenoCarcinoma of the prostate.
- Selection of optimal prostate specific antigen cutoffs for early detection of prostate Cancer: receiver operating characteristic curves.
- Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate Cancer: receiver operating characteri...
- Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate Cancer.
- Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate Cancer: results of a multicenter clinical trial of 6,63...
- Decision-making factors in the adjuvant treatment of operable breast Cancer.
- Chemotherapy in the treatment of esophageal Carcinoma.
- In vitro chemosensitivities of human tumor stem Cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
- Needle aspiration biopsy of Lung lesions at an Arizona Veterans Hospital.
- Adjuvant chemotherapy of coloRectal carcinoma.
- Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and Lymphoma: a University of Arizona and Southwest Oncology Group Study.
- Lack of inhibition by oxipurinol of 5-FU toxicity against human tumor Cell lines.
- Mineralocorticoid deficiency associated with aminoglutethimide therapy.
- Acute myelogenous leukaemia modulated by B12 deficiency: a case with bone marrow blast cell assay corroboration.
- Chemotherapy in the management of small cell lung Cancer.
- A reassessment of the clinical implications of the superior vena caval syndrome.
- Phase II trial of bisantrene in non-small cell lung Cancer.
- Chemohormonal therapy for advanced breast Cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC).
- Dilemmas in managing prostate Carcinoma. (Part I): Localized disease.
- Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon Cancer.
- Dilemmas in managing prostate Carcinoma (Part II): Metastatic disease.
- Cranial metastases from prostate Cancer simulating meningioma: report of two cases and review of the literature.
- Phase II trial of 4'-deoxydoxorubicin (esorubicin) in hormone resistant prostate Cancer.
- Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
- Growth in semisolid agar of prostate Cancer cells obtained from bone marrow aspirates.
- Cytogenetics of bone marrow fibroblastic Cells in idiopathic chronic myelofibrosis.
- Aminoglutethimide in metastatic adenoCarcinoma of the prostate.
- Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.
- IntraCellular adenosine triphosphate as a measure of human tumor Cell viability and drug modulated growth.
- The effect of prior adjuvant chemotherapy on survival in metastatic breast Cancer.
- Short-term chemotherapy of poor-prognosis metastatic breast Cancer with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group Study.
- Mantle zone Lymphoma with central nervous system involvement.
- Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
- Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate Cancer.
- The effect of digital Rectal examination on serum levels of prostatic-specific antigen.
- Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared.
- Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic Cancer.
- Cytokeratin characterization of human prostatic carcinoma and its derived Cell lines.
- The growth of benign prostatic hypertrophy in semisolid agar culture.
- Evaluation of menogaril in renal Cell carcinoma. A Southwest Oncology Group phase II study (8504).
- Predictive initial parameters for response of stage D prostate Cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin.
- Phase II evaluation of menogaril (NSC-269148) in non-small Cell lung carcinoma. A Southwest Oncology Group study.
- A phase II study of chemotherapy of metastatic coloRectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study.
- The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate Cancer.
- Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate Cancer.
- AdenoCarcinoma of the stomach: current knowledge and recent advances.
Schools
University Of MissouriColumbia School Of Medicine
Georgetown University Hospital
University Ariz
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Aetna HMO
- Aetna Savings Plus of AZ
- Choice Plus POS II
- American Republic
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Health Net PPO
- Medicare Advantage PFFS
- Humana
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Principal Life
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:Arizona State
- America's Top Doctors for Cancer
Education
-
University of Arizona -
Georgetown University Hospital -
University of Missouri-Columbia School of Medicine
Hospital
-
Banner - University Medical Center South
Drug Facts
| NPI NUMBER | 1700857166 | |
| NPPES Provider LastName | AHMANN | |
| NPPES Provider FirstName | FREDERICK | |
| NPPES Provider ZIPCode | 857191478 | |
| NPPES Provider State | AZ | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 513.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 34.0 | |
| Percent Opioid Claims | 6.63 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700857166 |
| Last Name Of The Provider | AHMANN |
| First Name Of The Provider | FREDERICK |
| View All |
Similar Doctors
|
|
Dr. Michael A. Boxer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravitharan Krishnadasan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emad Elquza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee D. Cranmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suresh B. Katakkar, MD |
|
|
Dr. Daniel O. Persky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashad A. Aboul-Nasr, MD |
|
|
Dr. Sarah G. McGinn, MD |
|
|
Dr. Dennis L. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mehrnoosh Zarkoob, MD |
|
|
Dr. Sydney E. Salmon, MD |
|
|
Dr. Wendy Y. Chen, DO |
|
|
Dr. Ana M. Lopez, MD |